Mirati Therapeutics, Inc. (MRTX) Financial Statements (2024 and earlier)

Company Profile

Business Address 3545 CRAY COURT
SAN DIEGO, CA 92121
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1,083,8371,491,3401,390,106415,050222,790150,837
Cash and cash equivalents235,260413,083885,56246,53532,694107,703
Short-term investments848,5771,078,257504,544368,515190,09643,134
Receivables3,7352,5132,304   
Inventory, net of allowances, customer advances and progress billings3,020     
Inventory3,020     
Prepaid expense15,20711,8958,1585,6721,2613,085
Other current assets    2,1191,8411,600
Other undisclosed current assets3,1622,2353,0751,566768237
Total current assets:1,108,9611,507,9831,403,643424,407226,660155,759
Noncurrent Assets
Operating lease, right-of-use asset36,122 39,890 
Property, plant and equipment17,54015,8247,8091,776473525
Long-term investments and receivables3,4658,21815,629   
Long-term investments3,4658,21815,629   
Intangible assets, net (including goodwill)14,914     
Intangible assets, net (excluding goodwill)14,914     
Restricted cash and investments  620    
Other noncurrent assets21,64519,0499,1576,0171,321962
Other undisclosed noncurrent assets  37,060    
Total noncurrent assets:93,68680,77172,4857,7931,7941,487
TOTAL ASSETS:1,202,6471,588,7541,476,128432,200228,454157,246
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:44,33434,39471,47248,08225,77513,644
Employee-related liabilities25,84513,9647,9155,8473,021
Accounts payable   18,11716,3678,5314,344
Accrued liabilities44,3348,549 21,29010,1546,256
Other undisclosed accounts payable and accrued liabilities   39,3912,5101,24323
Deferred revenue    824
Contract with customer, liability371
Other undisclosed current liabilities115,114109,264    
Total current liabilities:159,448143,65871,47248,90626,14613,644
Noncurrent Liabilities
Long-term debt and lease obligation:  45,87941,905   
Liabilities, other than long-term debt46,6832,1791,962999732314
Accounts payable and accrued liabilities    999732 
Other liabilities3,0222,1791,962  314
Operating lease, liability43,66145,87941,905 
Total noncurrent liabilities:46,68348,05843,867999732314
Total liabilities:206,131191,716115,33949,90526,87813,958
Equity
Equity, attributable to parent996,5161,397,0381,360,789382,295201,576143,288
Common stock585550403329
Additional paid in capital3,453,0663,099,9372,481,2181,144,667751,109594,407
Accumulated other comprehensive income (loss)(3,719)9,0689,7599,8899,4799,479
Accumulated deficit(2,452,889)(1,712,022)(1,130,238)(772,301)(559,045)(460,627)
Total equity:996,5161,397,0381,360,789382,295201,576143,288
TOTAL LIABILITIES AND EQUITY:1,202,6471,588,7541,476,128432,200228,454157,246

Income Statement (P&L) ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues12,43672,09213,3983,33512,926 
Gross profit:12,43672,09213,3983,33512,926 
Operating expenses(772,025)(645,273)(382,761)(225,439)(115,553)(71,535)
Operating loss:(759,589)(573,181)(369,363)(222,104)(102,627)(71,535)
Nonoperating income (expense)19,230(5,304)12,10012,2695,5291,371
Investment income, nonoperating   6743,4211,320266
Other nonoperating income (expense)19,230(5,304)11,4268,8484,2091,105
Loss from continuing operations before equity method investments, income taxes:(740,359)(578,485)(357,263)(209,835)(97,098)(70,164)
Other undisclosed loss from continuing operations before income taxes   (674)(3,421)(1,320)(266)
Loss from continuing operations before income taxes:(740,359)(578,485)(357,937)(213,256)(98,418)(70,430)
Income tax expense(508)(3,299)    
Loss from continuing operations:(740,867)(581,784)(357,937)(213,256)(98,418)(70,430)
Loss before gain (loss) on sale of properties:(581,784)(357,937)(213,256)(98,418)(70,430)
Net loss available to common stockholders, diluted:(740,867)(581,784)(357,937)(213,256)(98,418)(70,430)

Comprehensive Income ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(740,867)(581,784)(357,937)(213,256)(98,418)(70,430)
Comprehensive loss:(740,867)(581,784)(357,937)(213,256)(98,418)(70,430)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(12,787)(691)(130)410 (54)
Comprehensive loss, net of tax, attributable to parent:(753,654)(582,475)(358,067)(212,846)(98,418)(70,484)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: